Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

SHOCKING: 45 - You Need To See This

How common is Paxlovid rebound as Biden tests positive again for Covid?

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The Independent UK

The kids are all right: Fewer COVID-19 vaccine side effects

Australian children aged 5–15 years have reported fewer side effects in the days after receiving the mRNA COVID-19 vaccine than those in clinical trials.

The New Daily

Biden tests positive for COVID-19 again, returns to isolation

White House physician Dr. Kevin O’Connor said in a letter that Biden “has experienced no reemergence of symptoms, and continues to feel quite well.”

Chicago Sun-Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Andrew Hopkins of Exscientia: the man using AI to cure disease

The British scientist’s company employs artificial intelligence to drastically cut the time of drug development

The Guardian - UK

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga

Zenara Pharma gets CDSCO nod to make copy of Pfizer’s Paxlovid

Combi pack of Nirmatrelvir, Ritonavir tablets is for patients with moderate symptoms of Covid-19

The Hindu

Hyderabad-based Zenara Pharma gets CDSCO nod to manufacture generic version of Pfizer's Covid-19 pill

HYDERABAD: Hyderabad-based Zenara Pharma, a fully-owned subsidiary of Biophore India Pharmaceuticals, on Thursday said it has received emergency use authorisation (EUA) from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market in India a generic version of Pfizer’s Covid-19 pill Paxlovid for the treatment of patients with mild…

The Times of India

Read news from The Economist, FT, and more,
with one subscription

Check Out What Whales Are Doing With PFE

Someone with a lot of money to spend has taken a bearish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

What is Paxlovid? Everything you need to know about Joe Biden’s antiviral Covid drug treatment

Late-stage clinical trial found nearly 90 per cent effectiveness from antiviral pill

The Independent UK

Should you wait for the omicron booster? Why experts say you should 'get it now!'

If you're like most Americans, you've gotten your primary doses of a COVID-19 vaccine, but you haven't gotten the recommended booster shots. So if it's been several months since your last primary dose, you're probably due for a booster.

Los Angeles Times

3 High-Quality Stocks to Pick Up for the Second-Half

The bear market provides an opportunity for investors to buy shares of high-quality companies at attractive valuations. Below are 3 such stocks that investors should consider buying during this market correction: Elevance Health (ELVH), Pfizer (PFE), and Builders FirstSource (BLDR).

StockNews.com

High number of COVID-19 hospitalisations in ACT but only one in ICU

The ACT recorded 949 new COVID-19 cases in the 24 hours until 8pm Monday.

The Canberra Times

Man goes from council estate to €470m fortune with artificial intelligence

Andrew Hopkins grew up on a council estate but described how he has since swapped that life for one in the prestigious city of Oxford after setting up his company, Exscientia

Irish Mirror

Poor-quality medicines are everyone’s problem

COVID-19 has shown that regulatory processes can fail anywhere, allowing poor-quality medicines through. A new detection test could help shield consumers.

360info

Get all your
news in one place.

100's of premium titles.
One news app.

Wales Online

The man from a Welsh council estate now worth £400m thanks to an idea he had on his walk home

Andrew Hopkins has developed a biotech company called Exscientia which is revolutionising the industry

The Independent UK

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The New Daily

COVID-19 antivirals: Millions are now eligible, but the drugs are no substitute for boosters

Millions of Australians are now eligible for using antivirals to prevent serious illness or death from COVID-19. But it's complicated.

Los Angeles Times

Why Biden’s bout with COVID-19 is likely to be easier than Trump’s

Nearly two years separate the COVID-19 diagnoses of then-President Donald Trump and current President Joe Biden. In a pandemic that has engaged the full powers of the American medical and scientific establishments, that is a lifetime.

Get all your
news in one place.

100's of premium titles.
One news app.

WEKU

What to know about Paxlovid, the COVID drug President Biden is using to speed recovery

Paxlovid has been highly effective at reducing the risks of hospitalization and death, but some patients report a "Paxlovid rebound," in which the disease returns.

StockNews.com

Is Buying Pfizer Stock Right Now a Mistake?

The Independent UK

Biden tests positive for COVID-19, has 'very mild symptoms'

President Joe Biden says he's “doing great” after testing positive for COVID-19

The Independent UK

What is Paxlovid? Everything you need to know about the antiviral Covid drug being taken by Joe Biden

Late-stage clinical trial found nearly 90 per cent effectiveness from antiviral pill

Chicago Sun-Times

President Joe Biden tests positive for COVID-19

White House Press Secretary Karine Jean-Pierre said that President Biden was experiencing “mild symptoms” and has begun taking Paxlovid, an antiviral drug designed to reduce the severity of the disease.

Chronicle Live

Pfizer fined £63 million for overcharging NHS for life-saving medication

The Competition and Markets authority said that the ‘excessive’ price hikes by Pfizer and Flynn had meant that ‘patients and taxpayers lost out’

Evening Standard

Pfizer slapped with £63 million fine by CMA

Pharma firm Flynn was also charged £6.7 million as part of the CMA investigation

1 … 44 45 46 47

People

Andrés Manuel López Obrador

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.